Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
about
Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acidsNovel bile acid therapeutics for the treatment of chronic liver diseasesBreast Milk and Solid Food Shaping Intestinal ImmunityBile Acid Metabolism and Signaling in Cholestasis, Inflammation, and CancerBile acid metabolism and signalingFXR signaling in the enterohepatic systemFatty liver diseases, bile acids, and FXRBile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver DiseaseBile acid nuclear receptor FXR and digestive system diseasesKey discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decadesBile acid signaling in metabolic disease and drug therapyFarnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivoAlleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitisThe bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammationFarnesoid X Receptor an Emerging Target to Combat Obesity.Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases.Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease.Commensal bacteria at the interface of host metabolism and the immune system.Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention.Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease.Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease.Tissue specific induction of p62/Sqstm1 by farnesoid X receptor.Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistanceRecent advances in the development of farnesoid X receptor agonistsPharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.Impact of global Fxr deficiency on experimental acute pancreatitis and genetic variation in the FXR locus in human acute pancreatitis.Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity.Diet in the pathogenesis and treatment of inflammatory bowel diseasesBile acid mediated effects on gut integrity and performance of early-weaned pigletsSystematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids.Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion.Microbial transmission from mothers with obesity or diabetes to infants: an innovative opportunity to interrupt a vicious cycle.Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis.Advances in pharmacotherapy for primary biliary cirrhosis.Bile components and lecithin supplemented to plant based diets do not diminish diet related intestinal inflammation in Atlantic salmon
P2860
Q24628720-085D7745-1108-4407-9E99-13F35975134EQ26748613-945AAAF9-80E9-4F09-9C31-35E826930603Q26782801-E23ABF13-534E-485B-A3FB-EB7B8D092BA2Q26800206-1D74C7FB-05E8-4941-8023-33C9F02F9720Q27002873-20F4BDB7-7FA8-4D61-8642-15FA4AC892DBQ27014753-9F4C3DE8-3AAD-45A1-AF83-3BDF2AF8AC68Q28068199-18B793FF-1B52-4941-AD44-A45965272AD5Q28076064-3B4B6B65-B3CA-43C5-81BF-CD41D820A1CFQ28085493-674D3035-1F08-47C2-AAAC-76D136074176Q28240299-94EA18FD-3F9E-41F9-BF23-17269E95FB25Q28244875-0FB740B6-AC46-415D-88EB-0FE6525A84F5Q28296042-72565CBB-571B-4F99-9E2C-7C05C9DC1333Q28481350-D3603E82-7C16-4969-B910-121805135101Q28585275-126C245C-D18A-44E6-977E-0147526507DFQ30235507-3C8123A6-33CC-4103-BE7D-7A56E6B991A1Q30249313-21C72F13-A857-4C0D-B1C1-F65AD6CF9E79Q30490594-B5FDF920-695F-4562-9684-64135BB96D56Q33578547-F03459BC-BC64-4C45-8641-7B9584A9C6E6Q33661094-C73BAD55-DACD-44D6-9F79-D88DAA0A10C9Q33805839-801397BE-5D1E-487D-8108-DF299E74FFAFQ34009566-C1460679-1F75-4EBA-A758-CBDD28C6F12EQ34303001-20A4DF8D-C6D9-48E8-AA8B-F4F2628583AFQ34386625-0BB55B0E-4C7C-4B99-821C-9D984AB9BE19Q34396606-7F2DD2E3-5F0D-4044-A806-B77213A1276FQ34405939-80C5EBA6-390A-4A40-B05E-CB30D513566AQ34425909-444D6291-0183-43DB-A658-F317DB29056DQ34456568-A84A2D0B-CEEB-4B3C-8E6D-233DC2600CD1Q34464043-2F416D90-08DB-4614-ABAC-9A6DE3F18C59Q34493836-F7753F5F-4647-4EC0-87F6-D6B0C27F861DQ34627935-F3BB102E-631F-4214-B425-93C5030792B2Q35441714-0479E0BC-EA67-453D-B496-0876EBA1FB99Q35537121-7E8440ED-BF85-48A1-822C-23EDAA3FDED8Q35620287-2859E95F-0D48-4407-BA4C-4E5BC910D46EQ35724871-6FA1D0BE-7202-40D3-A264-74C00558A770Q35742169-47243BA7-56EF-4D35-81E4-B68E685F2234Q35817782-43E358A4-5E0D-4834-A503-DDC3E0D29BF0Q35914082-90DF6765-7415-420E-81EC-80ED1446EDB1Q36089858-33287F70-22C1-4EF2-8B03-B0EFBD0FC24BQ36116022-BCE15999-4EC9-43F4-88D2-BF434FB1787EQ36125569-AB86FA77-4292-4775-9710-E1F3CB2413B2
P2860
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
description
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2011
@ast
im Januar 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2011/04/01)
@sk
vědecký článek publikovaný v roce 2011
@cs
wetenschappelijk artikel (gepubliceerd op 2011/04/01)
@nl
наукова стаття, опублікована у квітні 2011
@uk
مقالة علمية (نشرت في أبريل 2011)
@ar
name
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@ast
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@en
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@nl
type
label
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@ast
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@en
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@nl
prefLabel
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@ast
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@en
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@nl
P2093
P50
P921
P3181
P356
P1433
P1476
Farnesoid X receptor activatio ...... in inflammatory bowel disease
@en
P2093
Antonio Moschetta
Bas Oldenburg
Ellen C L Willemsen
Karel J van Erpecum
Leo W J Klomp
Luciano Adorini
Marguerite E I Schipper
Peter D Siersema
Raffaella M Gadaleta
Silvio Danese
P304
P3181
P356
10.1136/GUT.2010.212159
P407
P577
2011-01-17T00:00:00Z